Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury  Ingeborg Friehs, MD, Adrian M Moran, MD, Christof Stamm, MD, Yeong-Hoon.

Slides:



Advertisements
Similar presentations
Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging  Keith A Horvath,
Advertisements

Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 
Kaviyanka Selvasandran, MS, Georges Makhoul, MD, MS, Prashant K
Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat  Ryuzo Bessho, MD, PhD, David J. Chambers,
Coronary Artery Bypass for Heart Failure in Ischemic Cardiomyopathy: 17-Year Follow- Up  Marco Pocar, MD, PhD, Andrea Moneta, MD, Adalberto Grossi, MD,
Therapeutic Effect of Midkine on Cardiac Remodeling in Infarcted Rat Hearts  Shinya Fukui, MD, Satoru Kitagawa-Sakakida, MD, PhD, Sin Kawamata, MD, PhD,
Direct epicardial shock wave therapy improves ventricular function and induces angiogenesis in ischemic heart failure  Daniel Zimpfer, MD, Seyedhossein.
Neovasculogenic Therapy to Augment Perfusion and Preserve Viability in Ischemic Cardiomyopathy  Pavan Atluri, MD, George P. Liao, MB, Corinna M. Panlilio,
Electron transport chain dysfunction in neonatal pressure-overload hypertrophy precedes cardiomyocyte apoptosis independent of oxidative stress  Eric.
Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: Safety and efficacy studies 
Optimal time for cardiomyocyte transplantation to maximize myocardial function after left ventricular injury  Ren-Ke Li, MD, PhD, Donald A.G. Mickle,
Comparative effects of mesenchymal progenitor cells, endothelial progenitor cells, or their combination on myocardial infarct regeneration and cardiac.
Hypercholesterolemia Impairs the Myocardial Angiogenic Response in a Swine Model of Chronic Ischemia: Role of Endostatin and Oxidative Stress  Munir Boodhwani,
Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 
Protective effects of protein kinase C during myocardial ischemia require activation of phosphatidyl-inositol specific phospholipase C  Mamoru Munakata,
Mechanism of myocardial ischemia with an anomalous left coronary artery from the right sinus of Valsalva  Carlo R. Bartoli, PhD, William B. Wead, PhD,
The effect of estrogen on diabetic wound healing is mediated through increasing the function of various bone marrow-derived progenitor cells  Ying Zhuge,
Combination of stromal-derived factor-1α and vascular endothelial growth factor gene- modified endothelial progenitor cells is more effective for ischemic.
Gefeng Li, John A. Sullivan, John M. You, Richard I. Hall 
Rapamycin Blocks Fibrocyte Migration and Attenuates Bronchiolitis Obliterans in a Murine Model  Jacob R. Gillen, MD, Yunge Zhao, MD, PhD, David A. Harris,
Meena Nathan, MD, Ingeborg Friehs, MD, Yeong-Hoon Choi, MD, Douglas B
Ryan M. McEnaney, MD, Ankur Shukla, MD, Michael C
Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34- positive endothelial cells in a hindlimb ischemia model: Implications for.
Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF  G.Chad Hughes, MD, Shankha S Biswas, MD, Bangliang.
Changfa Guo, MD, Husnain Kh
Diazoxide amelioration of myocardial injury and mitochondrial damage during cardiac surgery  James D McCully, PhD, Hidetaka Wakiyama, MD, Douglas B Cowan,
Pravastatin Improves Remodeling and Cardiac Function After Myocardial Infarction by an Antiinflammatory Mechanism Rather than by the Induction of Angiogenesis 
Nathalie Roy, MD, Ingeborg Friehs, MD, Douglas B
A novel vascularized patch enhances cell survival and modifies ventricular remodeling in a rat myocardial infarction model  Qi Zhou, MD, PhD, Jian-Ye.
Toru Okamura, MD, Nobuyuki Ishibashi, MD, T
Akihiko Ohkado, MD, Hung Cao-Danh, PhD, K. Eric Sommers, MD, Pedro J
Septal Myectomy Results in Regression of Left Ventricular Hypertrophy in Patients With Hypertrophic Obstructive Cardiomyopathy  Subrato J. Deb, MD, Hartzell.
Increased susceptibility of hypertrophied hearts to ischemic injury
Injectable Small Intestine Submucosal Extracellular Matrix in an Acute Myocardial Infarction Model  Hadi Daood Toeg, MD, MS, Rashmi Tiwari-Pandey, PhD,
Vascular Endothelial Growth Factor Prevents Endothelial-to-Mesenchymal Transition in Hypertrophy  Ben M.-W. Illigens, MD, Alejandra Casar Berazaluce,
Therapeutic Potential of Human Umbilical Cord Derived Stem Cells in a Rat Myocardial Infarction Model  Kai Hong Wu, MD, PhD, Bin Zhou, PhD, Cun Tao Yu,
Leptin receptor is elevated in carotid plaques from neurologically symptomatic patients and positively correlated with augmented macrophage density  Jacob.
Endogenous myocardial angiogenesis and revascularization using a gastric submucosal patch  Marc A Ruel, MD, MPh, Frank W Sellke, MD, Cesario Bianchi,
Calpain inhibition improves collateral-dependent perfusion in a hypercholesterolemic swine model of chronic myocardial ischemia  Ashraf A. Sabe, MD, Brittany.
Prolonged preservation of the blood-perfused canine heart with glycolysis-promoting solution  Koh Takeuchi, MD, Hung Cao-Danh, PhD, Akihiko Kawai, MD,
Erin E. Tansey, BS, Kevin F. Kwaku, MD, PhD, Peter E
Improvement of cardiac function in the failing rat heart after transfer of skeletal myoblasts engineered to overexpress placental growth factor  Matthias.
Terminal Warm Blood Cardioplegia Improves Cardiac Function Through Microtubule Repolymerization  Hironori Tenpaku, MD, Koji Onoda, MD, Kyoko Imanaka-Yoshida,
Effects of cardioplegia on vascular function and the “no-reflow" phenomenon after ischemia and reperfusion: Studies in the isolated blood-perfused rat.
Continuous-Flow Left Ventricular Assist Device Implantation in Patients With a Small Left Ventricle  Masashi Kawabori, MD, Chitaru Kurihara, MD, Tadahisa.
Tormod S. Westvik, MD, Tamara N
Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium  Yeong-Hoon Choi, MD, Douglas B. Cowan, PhD,
Extracorporeal shock wave therapy ameliorates secondary lymphedema by promoting lymphangiogenesis  Masayuki Kubo, PhD, Tao-Sheng Li, MD, PhD, Takahiro.
Myocardial rescue with autologous mitochondrial transplantation in a porcine model of ischemia/reperfusion  Aditya K. Kaza, MD, Isaac Wamala, MD, Ingeborg.
J. Trent Magruder, MD, Todd C
Modification of Infarct Material Properties Limits Adverse Ventricular Remodeling  Masato Morita, MD, Chad E. Eckert, PhD, Kanji Matsuzaki, MD, PhD, Mio.
Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts  Mauricio A. Retuerto, BS, James T. Beckmann,
Experimental study of intermittent crossclamping with fibrillation and myocardial protection: Reduced injury from shorter cumulative ischemia or intrinsic.
Efficacy of Therapeutic Angiogenesis by Intramyocardial Injection of pCK-VEGF165 in Pigs  Jae-Sung Choi, MD, PhD, Ki-Bong Kim, MD, PhD, Woong Han, DVM,
Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart  Naosumi Sekiya, MD, Goro Matsumiya, MD, PhD, Shigeru.
Up-regulation of vascular endothelial growth factor mrna and angiogenesis after transmyocardial laser revascularization  Keith A Horvath, MD, Elaine Chiu,
Aging reduces postischemic recovery of coronary endothelial function
Elimination of Ischemic Mitral Regurgitation Does Not Alter Long-Term Left Ventricular Remodeling in the Ovine Model  Kanji Matsuzaki, MD, PhD, Masato.
Inhibition of Glycogen Synthase Kinase-3β Improves Tolerance to Ischemia in Hypertrophied Hearts  Rodrigo Barillas, MD, MBA, Ingeborg Friehs, MD, Hung.
The Annals of Thoracic Surgery
Myocardial functional recovery after fibroblast growth factor 2 gene therapy as assessed by echocardiography and magnetic resonance imaging  Keith A Horvath,
Comparison of developmental endothelial locus-1 angiogenic factor with vascular endothelial growth factor in a porcine model of cardiac ischemia  Murray.
Vascular Endothelial Growth Factor Attenuates Myocardial Ischemia-Reperfusion Injury  Zhengyu Luo, Maurizio Diaco, Toyoaki Murohara, Napoleone Ferrara,
Adenosine-enhanced ischemic preconditioning provides myocardial protection equal to that of cold blood cardioplegia  James D McCully, PhD, Masahisa Uematsu,
Vascular Endothelial Growth Factor Receptor Upregulation in Response to Cell-Based Angiogenic Gene Therapy  Terrence M. Yau, MD, MS, Guangming Li, MD,
Munir Boodhwani, MD, MMSc, Neel R
High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine 
Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined.
The Annals of Thoracic Surgery
Koh Takeuchi, MD, Pedro J. del Nido, MD, Andra E
Presentation transcript:

Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury  Ingeborg Friehs, MD, Adrian M Moran, MD, Christof Stamm, MD, Yeong-Hoon Choi, MD, Douglas B Cowan, PhD, Francis X McGowan, MD, Pedro J del Nido, MD  The Annals of Thoracic Surgery  Volume 77, Issue 6, Pages 2004-2010 (June 2004) DOI: 10.1016/j.athoracsur.2003.11.003

Fig 1 (A) Representative sections of control, untreated, and VEGF treated hypertrophied hearts perfused with FITC-labeled lectin. Myocytes stained in red with desmin and nuclei stained with DAPI in blue. (B) Cumulative data of all vessels identified by the computer image analyzer within a calibrated graticule of randomly selected fields are summarized (*p < 0.05; versus untreated hypertrophied hearts). (C) Number of microvessels detected after FITC-labeled lectin perfusion, expressed per number DAPI-stained nuclei (*p < 0.05; versus untreated hypertrophied hearts). □ = control; ■ = untreated hypertrophy; ▨ = VEGF treated hypertrophy. (DAPI = 4',6-diamidino-2-phenylindole; FITC = fluorescein-isothiocyanate-conjugated; VEGF = vascular endothelial growth factor.) The Annals of Thoracic Surgery 2004 77, 2004-2010DOI: (10.1016/j.athoracsur.2003.11.003)

Fig 2 Coronary flow rate adjusted to (A) gram of total heart weight and (B) gram of LV weight, respectively, is shown with solid bars for untreated hypertrophied hearts, striped bars for VEGF treated hypertrophied hearts, and open bars for controls (*p < 0.05; versus untreated hypertrophy). (LV = left ventricular; VEGF = vascular endothelial growth factor.) The Annals of Thoracic Surgery 2004 77, 2004-2010DOI: (10.1016/j.athoracsur.2003.11.003)

Fig 3 Glucose transport was improved reaching levels found in nonhypertrophied hearts following VEGF treatment (*p < 0.05 versus untreated hypertrophy). ♦ = untreated hypertrophy; ■ = VEGF treated hypertrophy. (VEGF = vascular endothelial growth factor.) The Annals of Thoracic Surgery 2004 77, 2004-2010DOI: (10.1016/j.athoracsur.2003.11.003)

Fig 4 Preischemic developed pressure, indicated by the open bars, and postischemic developed pressure, indicated by the solid bars, showed improved postischemic recovery of myocardial function in VEGF treated hypertrophied hearts compared to untreated hypertrophied hearts (*p < 0.001; versus preischemia; #p < 0.001; versus untreated hypertrophied hearts). (VEGF = vascular endothelial growth factor.) The Annals of Thoracic Surgery 2004 77, 2004-2010DOI: (10.1016/j.athoracsur.2003.11.003)

Fig 5 (A) This graph shows LV mass-to-cavity volume measurements as indicators of hypertrophic growth. The VEGF treated hearts maintained an increase in LV mass over an extended period of time beyond the time point when untreated hypertrophied hearts already showed severe signs of ventricular dilatation (*p < 0.01; for differences between both group and time influence). (B) Measurement of contractility, depicted as Z-scores (data calculated based on previous echocardiographic measurements of nonhypertrophied control hearts over time) indicates that VEGF treatment preserved contractile function within the normal range at week 6 (−0.08 ± 0.48), while contractility fell significantly at the same time period in untreated hypertrophied hearts (−1.39 ± 0.35; p = 0.004). ♦ = untreated hypertrophy; ■ = VEGF treated hypertrophy. (LV = left ventricular; VEGF = vascular endothelial growth factor.) The Annals of Thoracic Surgery 2004 77, 2004-2010DOI: (10.1016/j.athoracsur.2003.11.003)